Purpose: To compare the degree of enhancement of the perilymph between two macrocyclic gadolinium-based contrast agents (gadobutrol and gadoterate meglumine) in patients with Meniere's disease at 3-T magnetic resonance imaging (MRI).
Materials and methods: The MRI examinations of 20 patients with Meniere's disease obtained 4hours after a single intravenous dose of macrocyclic gadolinium-based contrast agents were retrospectively compared. Ten patients (median age: 58.5 years; median body mass index [BMI]: 25) have received a single intravenous dose of gadoterate meglumine and 10 patients (median age: 45.5 years; median BMI: 25.4) have received a single-dose of gadobutrol. Two radiologists independently measured the signal intensity ratio (SIR) by using region of interest analysis and performed a visual assessment in order to evaluate the perilymph of each semicircular canal and of the vestibule.
Results: No differences in SIR of the symptomatic ear were found between gadobutrol (median SIR: 1.58) and gadoterate meglumine (median SIR: 1.3) (P=0.18). The SIR of the contralateral asymptomatic ear was significantly greater with gadobutrol (median: 1.62) than with gadoterate meglumine (median: 1.21) (P=0.009). No differences in endolymphatic structures visualization were found between gadobutrol and gadoterate meglumine in the symptomatic ears (P=0.27) but gadobutrol allowed a better assessment of endolymphatic structures and semicircular canals in the asymptomatic ear (P<0.001).
Conclusion: Gadobutrol and gadoterate meglumine provide similar degrees of enhancement of the symptomatic ear in patients with Meniere's disease but gadobutrol provides better anatomical details regarding endolymphatic space and semicircular canals of asymptomatic, contralateral ear.
Keywords: Endolymphatic hydrops; Gadolinium-based contrast agent; Inner ear; Magnetic resonance imaging (MRI); Meniere's disease.
Copyright © 2018 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.